This is a working overview of IGF-1, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-19. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Identity and purity are judged through a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact peptide from truncated, oxidized, and deamidated variants, and the resulting peak-area percentages yield a purity figure. Electrospray ionization mass spectrometry confirms the expected molecular mass and can expose unanticipated modifications. Amino acid analysis and peptide mapping support sequence fidelity, while water content, pH, sterility, and bacterial endotoxin testing describe the physical and microbiological attributes of a finished lot.
Regulatory position depends on jurisdiction and on the form in which the material is sold. A branded product holds approval in the United States for a defined indication, and prescribing is confined to that label. Material marketed for laboratory research is not evaluated for human use and carries no such clearance. Independent verification therefore rests on certificates of analysis, third-party testing, and documented chain of custody. The substance also appears on the World Anti-Doping Agency prohibited list within the category covering growth hormone-releasing factors.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Fluorescent chloride sensors are used for chemical analysis. The discoveries of chloride (Cl−) participations in physiological processes stimulates the measurements of intracellular Cl− in live cells and the development of fluorescent tools referred below. quinolinium - based Cl− indicators are based on the capability of halides to quench the fluorescence of heterocyclic organic compounds with quaternary nitrogen. Fluorescence is quenched by a collision mechanism with a linear Stern–Volmer relationship: F 0 F = 1 + K ( [ C l − ] ) {\displaystyle {\frac {F_{0}}{F}}=1+K([Cl^{-}])} where: F 0 {\displaystyle F_{0}} is the fluorescence in the absence of halide F {\displaystyle F} is the fluorescence in the presence of halide K {\displaystyle K} is the Stern–Volmer quenching constant, which depends on the chloride concentration, [ C l − ] {\displaystyle [Cl^{-}]}
=== Neutron activation === Molybdenum-99, which decays to form technetium-99m, can be formed by the neutron activation of molybdenum-98. When needed, other technetium isotopes are not produced in significant quantities by fission, but are manufactured by neutron irradiation of parent isotopes (for example, technetium-97 can be made by neutron irradiation of ruthenium-96).
=== 2026 Iran war === Following the assassination of Ali Khamenei during the 2026 Iran war, Badr Organization leader Hadi al-Amiri pledged allegiance to the new supreme leader of Iran, Mojtaba Khamenei.
== Derivatives == Coicenals A-C share the common carbon skeleton of 10-(sec-butyl)-6-hydroxy-1,7,9-trimethyl-1,6,7,8,9,9a-hexahydro-1,4-methanobenzo[d]oxepin-2(4H)-ylidene)acetaldehyde. The molecular formulas of each derivative were determined via high-resolution electrospray ionization mass spectrometry. The R group of Coicenal A is a hydrogen. Coicenal B contains a succinate group for its R group. The R group of Coicenal C is a methyl succinate group. Coicenal D contains a different carbon skeleton than A-C and a succinate group for its R group.
Sources: en.wikipedia.org
For services to the community in Crowborough, East Sussex. Dorothy Christine Flynn. For services to Young People in Winchester, Hampshire. Thomas William Foley, Warder Supervisor, National Gallery. Patricia Folland. For services to Young People in South Shields, Tyne and Wear. Pauline Anne Force, School Secretary, Oakfield County Primary Junior School, Dartford, Kent. For services to Education. James Paton Hunter Ford, Team Leader/Instructor, Steelwork, Yarrow Shipbuilders Ltd. For services to the Shipbuilding Industry. Robert Peter Ford, Sorter, Parcelforce, East Midlands. For services to the Post Office and to Industrial Relations. Audley Moraise Forrester, Interchange Manager, South Yorkshire Passenger Transport Executive. For services to Public Transport. John Robert Fortnam, Group Purchase Manager, Aerospace Group, Rolls-Royce plc. For services to the Aerospace Industry. Alfred Foster, Founder, African Leprosy Aid. For charitable services. John Christopher Foxley, Water Supply Manager, Southern Water. For services to the Water Industry. Annis Grace Campbell Frackelton. For services to Family Care in Edinburgh. Lesley Margaret Freeman, Range D, Her Majesty's Treasury. Michael William Thomas Freeman, Inspector, Lincolnshire Constabulary. For services to the community. Denzil Kingson Freeth. For services to the Church of England in London. Patricia Froomberg. For services to disabled people. Norah Fryer. For services to Elderly People in Church Lawton, Cheshire. Michael Fuller, Laboratory Services Manager, Laboratory of Molecular Biology. For services to Biology.
==== Comparison ==== Spironolactone, the 5α-reductase inhibitor finasteride, and the nonsteroidal antiandrogen flutamide all appear to have similar effectiveness in the treatment of hirsutism. Some clinical research, though, has found that the effectiveness of spironolactone for hirsutism is greater than that of finasteride, but is less than that of flutamide. The combination of spironolactone with finasteride is more effective than either alone for hirsutism and the combination of spironolactone with a birth-control pill is more effective than a birth-control pill alone. One study showed that spironolactone or the steroidal antiandrogen cyproterone acetate both in combination with a birth-control pill had equivalent effectiveness for hirsutism. Spironolactone is considered to be a first-line treatment for hirsutism, finasteride and the steroidal antiandrogen cyproterone acetate are considered to be second-line treatments, and flutamide is no longer recommended for hirsutism due to liver toxicity concerns. The nonsteroidal antiandrogen bicalutamide is an alternative option to flutamide with improved safety. The combination of spironolactone with a birth-control pill in the treatment of acne appears to have similar effectiveness to a birth-control pill alone and the combination of a birth-control pill with cyproterone acetate, flutamide, or finasteride. However, this was based on low- to very low-quality evidence.
are calculated for a short time frame, and the matrices for longer periods of time are calculated by assuming mutations follow a Markov chain model. The base unit of time for the PAM matrices is the time required for 1 mutation to occur per 100 amino acids, sometimes called 'a PAM unit' or 'a PAM' of time. This is precisely the duration of mutation assumed by the PAM1 matrix. The constant
=== Other === Cyclodextrins bind fragrances. Such devices are capable of releasing fragrances when heated, such as by ironing, body heat, or a dryer. A common application is a typical 'dryer sheet'. They are also the main ingredient in Febreze, which claims that the β-cyclodextrins "trap" odor-causing compounds, thereby reducing the odor. Cyclodextrins are also used to produce alcohol powder by encapsulating ethanol. The powder produces an alcoholic beverage when mixed with water, or can also be taken in a pill. The approval of powdered alcohol by the FDA in 2014 was met with wide-spread bans and backlash in the United States.
=== Insulin-like growth factors === Insulin-like growth factors (IGF) assist bone growth in the body. IGF's are single-chain polypeptides that are similarly structured to insulin. There are 2 IGFs: Insulin-like growth factor 1 (IGF-1), and Insulin-like growth factor 2 (IGF-2). IGF-1 is induced by growth hormone (GH), and targets cartilage, stimulating cell bone cell proliferation. Studies carried out by Yakar S, Rosen CJ have shown in animal models that IGF-1 can enhance longitudinal growth, periosteal circumference, and bone mineral density. IGF-1 is responsible for increasing overall body size, longitudinal bone size, and height, especially during puberty.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
Reconstituted solutions are kept cold and used within the period stated on the label or certificate. Repeated warming and cooling cycles should be avoided because they encourage aggregation and gradual loss of potency.